Nucleotide oligomerization domain 2 polymorphisms in patients with intestinal failure.

MedStar author(s):
Citation: Journal of Gastroenterology & Hepatology. 28(2):309-13, 2013 Feb.PMID: 23173613Institution: MedStar Washington Hospital CenterDepartment: Surgery/TransplantationForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov'tSubject headings: *Immunity, Innate/ge [Genetics] | *Intestinal Diseases/ge [Genetics] | *Nod2 Signaling Adaptor Protein/ge [Genetics] | *Polymorphism, Single Nucleotide | Adolescent | Adult | Case-Control Studies | Chi-Square Distribution | Child | Child, Preschool | DNA Mutational Analysis | Female | Gene Frequency | Genetic Predisposition to Disease | Haplotypes | Homeostasis | Humans | Infant | Infant, Newborn | Intestinal Diseases/im [Immunology] | Male | Odds Ratio | Phenotype | Young AdultISSN:
  • 0815-9319
Name of journal: Journal of gastroenterology and hepatologyAbstract: AIM: To evaluate the prevalence of NOD2 mutations in a population with IF as well as its association with the different conditions causing this problem.BACKGROUND: Nucleotide oligomerization domain 2 (NOD2) has been associated with intestinal immunity after the discovery that its polymorphisms are linked to Crohn's disease (CD). Intestinal failure (IF) represents a wider spectrum of diseases where intestinal homeostasis has been disrupted.CONCLUSION: Our finding supports the importance of NOD2 in the maintenance of intestinal immune homeostasis and may be important to a variety of intestinal stressors. 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.METHODS: One hundred ninety-two consecutive patients with IF and 103 healthy controls were genotyped for the three most common NOD2 polymorphisms. Genotypes were compared between the groups and were related to the entities causing IF.RESULTS: A high percentage (26%) of patients had at least one of the three most common NOD2 polymorphisms, while only a 4.8% of healthy controls had a mutant genotype. In patients with IF, specific mutations for the 702W, 908R and 1007fs alleles were 11, 5 and 12.5%, respectively, compared with 0.9% (P=0.0003), 1.9% (P=0.1) and 1.9% (P=0.001) in the control group. If we consider patients with any cause of IF other than CD, the percentage is still as high as 18.8%, with specific mutation frequencies of 7.6% (702W; P=0.01), 5.8% (908R; P=0.1) and 8.2% (1007fs; P=0.002). We could not establish an association between a NOD2 mutant genotype with any other specific clinical condition other than CD.All authors: Abdo J, Fishbein T, Girlanda R, Guerra JF, Hawksworth J, Island E, Kaufman S, Lough D, Mastumoto C, Shetty K, Zasloff MDigital Object Identifier: Date added to catalog: 2013-09-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 23173613

AIM: To evaluate the prevalence of NOD2 mutations in a population with IF as well as its association with the different conditions causing this problem.

BACKGROUND: Nucleotide oligomerization domain 2 (NOD2) has been associated with intestinal immunity after the discovery that its polymorphisms are linked to Crohn's disease (CD). Intestinal failure (IF) represents a wider spectrum of diseases where intestinal homeostasis has been disrupted.

CONCLUSION: Our finding supports the importance of NOD2 in the maintenance of intestinal immune homeostasis and may be important to a variety of intestinal stressors. 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

METHODS: One hundred ninety-two consecutive patients with IF and 103 healthy controls were genotyped for the three most common NOD2 polymorphisms. Genotypes were compared between the groups and were related to the entities causing IF.

RESULTS: A high percentage (26%) of patients had at least one of the three most common NOD2 polymorphisms, while only a 4.8% of healthy controls had a mutant genotype. In patients with IF, specific mutations for the 702W, 908R and 1007fs alleles were 11, 5 and 12.5%, respectively, compared with 0.9% (P=0.0003), 1.9% (P=0.1) and 1.9% (P=0.001) in the control group. If we consider patients with any cause of IF other than CD, the percentage is still as high as 18.8%, with specific mutation frequencies of 7.6% (702W; P=0.01), 5.8% (908R; P=0.1) and 8.2% (1007fs; P=0.002). We could not establish an association between a NOD2 mutant genotype with any other specific clinical condition other than CD.

English

Powered by Koha